Skip to main content
Top
Published in: Internal and Emergency Medicine 2/2020

01-03-2020 | Magnetic Resonance Imaging | CE-Research Letter to the Editor

Liver alterations in anorexia nervosa are not caused by insulin resistance

Authors: Alice Fanin, Lucia Miele, Emanuela Bertolini, Alessia Giorgini, Antonio Ettore Pontiroli, Alberto Benetti

Published in: Internal and Emergency Medicine | Issue 2/2020

Login to get access

Abstract

Background

Liver dysfunction has been widely reported in connection with anorexia nervosa (AN) but the pathogenesis of these alterations has never been fully understood despite reported theories about the presence of insulin resistance (IR) and non-alcoholic fatty liver disease (NAFLD). The aim of this study is to investigate if hypertransaminasemia in AN is linked to IR and NAFLD.

Methods

Anthropometric data and laboratory exams of 34 patients and 34 controls were analyzed, including alanine-aminotransferase, aspartate-aminotransferase and homeostatic model assessment of insulin resistance (HOMA-IR) index. All subjects also underwent magnetic resonance imaging (MRI), ultrasonography (US), and transient elastography (TE).

Results

Evidence of increased alanine aminotransferase in AN patients was confirmed in our sample together with a lower HOMA-IR index compared to controls. Positive results in US appeared in 16 patients vs none in controls (p = 0.0007); patients with liver parenchyma abnormalities in US were not different than normal-US patients in any of the studied variables. Only one patient showed non-alcoholic fatty liver disease in MRI while abnormal TE was found in four patients and never in controls.

Conclusions

Liver damage suggested by increased serum liver enzymes cannot be due to liver steatosis but potentially to a different liver disease (not identified by MRI) or to an early liver fibrosis not associated with an insulin-resistant status.
Literature
5.
go back to reference Fukushima M, Nakai Y, Taniguchi A, Imura H, Nagata I, Tokuyama K (1993) Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis. Metab Clin Exp 42(9):1164–1168CrossRef Fukushima M, Nakai Y, Taniguchi A, Imura H, Nagata I, Tokuyama K (1993) Insulin sensitivity, insulin secretion, and glucose effectiveness in anorexia nervosa: a minimal model analysis. Metab Clin Exp 42(9):1164–1168CrossRef
11.
go back to reference Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR (2005) Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39(7):619–625CrossRef Fishbein M, Castro F, Cheruku S, Jain S, Webb B, Gleason T, Stevens WR (2005) Hepatic MRI for fat quantitation: its relationship to fat morphology, diagnosis, and ultrasound. J Clin Gastroenterol 39(7):619–625CrossRef
12.
go back to reference Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA (1997) Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 15(3):287–293CrossRef Fishbein MH, Gardner KG, Potter CJ, Schmalbrock P, Smith MA (1997) Introduction of fast MR imaging in the assessment of hepatic steatosis. Magn Reson Imaging 15(3):287–293CrossRef
Metadata
Title
Liver alterations in anorexia nervosa are not caused by insulin resistance
Authors
Alice Fanin
Lucia Miele
Emanuela Bertolini
Alessia Giorgini
Antonio Ettore Pontiroli
Alberto Benetti
Publication date
01-03-2020
Publisher
Springer International Publishing
Published in
Internal and Emergency Medicine / Issue 2/2020
Print ISSN: 1828-0447
Electronic ISSN: 1970-9366
DOI
https://doi.org/10.1007/s11739-019-02227-9

Other articles of this Issue 2/2020

Internal and Emergency Medicine 2/2020 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine